Advisors Asset Management, Inc. Cellectis S.A. Transaction History

Advisors Asset Management, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$10.15 - $16.89 $125,788 - $209,317	-12,393 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$14.6 - $20.6 $139,269 - $196,503	-9,539 Reduced 43.49%	12,393 $193,000
Q1 2019 May 15, 2019	SELL	$15.53 - $19.75 $3,758 - $4,779	-242 Reduced 1.09%	21,932 $402,000
Q4 2018 Jan 31, 2019	SELL	$15.58 - $28.41 $11,124 - $20,284	-714 Reduced 3.12%	22,174 $369,000
Q3 2018 Nov 15, 2018	SELL	$25.99 - $30.6 $30,434 - $35,832	-1,171 Reduced 4.87%	22,888 $646,000

Q2 2018 Aug 22, 2018	BUY	$27.78 - $38.53 $645,773 - $895,668	23,246 Added 2859.29%	24,059 $681,000
Q2 2018 Aug 15, 2018	SELL	$27.78 - $38.53 $686,416 - $952,037	-24,709 Reduced 96.81%	813 $681,000
Q1 2018 May 15, 2018	SELL	$27.78 - $35.19 $36,752 - $46,556	-1,323 Reduced 4.93%	25,522 $797,000
Q4 2017 Feb 13, 2018	BUY	$23.33 - $35.01 $99,222 - $148,897	4,253 Added 18.83%	26,845 $783,000
Q3 2017 Nov 07, 2017	BUY	$21.65 - $32.18 $489,116 - $727,010	22,592	22,592 $643,000

9.73M

30.9K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $101M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Advisors Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisors Asset Management, Inc. with notifications on news.